How does 1SXP's PE Ratio compare to its peers?

1SXP is good value based on its Price-To-Earnings Ratio (27.3x) compared to the peer average (57.7x).

How does 1SXP's PE Ratio compare vs other companies in the European Life Sciences Industry?

1SXP is good value based on its Price-To-Earnings Ratio (27.3x) compared to the European Life Sciences industry average (37.1x).

What is 1SXP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 1SXP's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 1SXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1SXP (€26.72) is trading below our estimate of [[fair value]] (€29.31)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

SCHOTT Pharma KGaA (WBAG:1SXP) - Stock Price, News & Analysis

1SXP Stock Overview

Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. More details

1SXP fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 8.8% below our estimate of its fair value

Earnings are forecast to grow 15.85% per year

Earnings have grown 15.4% per year over the past 5 years

Analysts in good agreement that stock price will rise by 27.6%

Risk Analysis

Volatile share price over the past 3 months compared to the Austrian market

SCHOTT Pharma AG & Co. KGaA Competitors

Syngene International

NSEI:SYNGENE

₹359.3b

Syneos Health

NasdaqGS:SYNH

US$4.5b

Stevanato Group

NYSE:STVN

US$5.4b

Sotera Health

NasdaqGS:SHC

US$3.6b

Price History & Performance

Summary of all time highs, changes and price drops for SCHOTT Pharma KGaA
Historical stock prices
Current Share Price	€26.72
52 Week High	€41.60
52 Week Low	€25.80
Beta	0
11 Month Change	-15.23%
3 Month Change	-17.48%
1 Year Change	-6.70%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-14.90%

Recent updates

Shareholder Returns

	1SXP	AT Life Sciences	AT Market
7D	3.6%	2.2%	-0.6%
1Y	-6.7%	3.6%	2.5%

Return vs Industry: 1SXP underperformed the Austrian Life Sciences industry which returned 3.6% over the past year.

Return vs Market: 1SXP underperformed the Austrian Market which returned 2.5% over the past year.

Price Volatility

Is 1SXP's price volatile compared to industry and market?
1SXP volatility
1SXP Average Weekly Movement	5.4%
Life Sciences Industry Average Movement	6.2%
Market Average Movement	3.6%
10% most volatile stocks in AT Market	6.6%
10% least volatile stocks in AT Market	1.8%

Stable Share Price: 1SXP's share price has been volatile over the past 3 months compared to the Austrian market.

Volatility Over Time: 1SXP's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.

About the Company

Founded	Employees	CEO	Website
1884	4,681	n/a	www.schott-pharma.com

SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. The company offers prefillable glass or polymer syringes, glass vials, cartridges, and ampoules. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container.

SCHOTT Pharma AG & Co. KGaA Fundamentals Summary

How do SCHOTT Pharma KGaA's earnings and revenue compare to its market cap?
1SXP fundamental statistics
Market cap	€4.10b
Earnings (TTM)	€150.41m
Revenue (TTM)	€948.56m

27.3x

P/E Ratio

4.3x

P/S Ratio

Is 1SXP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1SXP income statement (TTM)
Revenue	€948.56m
Cost of Revenue	€624.35m
Gross Profit	€324.20m
Other Expenses	€173.79m
Earnings	€150.41m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Dec 12, 2024

Earnings per share (EPS)	1.00
Gross Margin	34.18%
Net Profit Margin	15.86%
Debt/Equity Ratio	24.5%

How did 1SXP perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

15%

Payout Ratio